Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125259951 | 12525995 | 1 | I | 20151221 | 20160705 | 20160705 | EXP | KR-MLMSERVICE-20160609-0116426-3 | KR-ACCORD-042092 | ACCORD | LEE HS, UETA M, KIM MK, SEO KY, SOTOZONO C, KINOSHITA S ET AL. ANALYSIS OF OCULAR MANIFESTATION AND GENETIC ASSOCIATION OF ALLOPURINOL-INDUCED STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS IN SOUTH KOREA.CORNEA. 2015; 35(2):199-204 | 71.00 | YR | M | Y | 0.00000 | 20160705 | MD | KR | KR |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125259951 | 12525995 | 1 | PS | ALLOPURINOL. | ALLOPURINOL | 1 | U | 203154 | |||||||||||
125259951 | 12525995 | 2 | C | LOSARTAN. | LOSARTAN | 1 | 0 | ||||||||||||
125259951 | 12525995 | 3 | C | GLIMEPIRIDE. | GLIMEPIRIDE | 1 | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125259951 | 12525995 | 1 | Product used for unknown indication |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125259951 | 12525995 | OT |
125259951 | 12525995 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125259951 | 12525995 | Conjunctival hyperaemia | |
125259951 | 12525995 | Corneal epithelium defect | |
125259951 | 12525995 | Stevens-Johnson syndrome |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |